ÖZET
Sonuç:
Gastrik sıvıda da mevcut olan kalprotektin, benign-malign ülser ayırıcı tanısında kullanılabilir. Gastrik kanser erken tanısında da kullanılabilirliğini ispatlamak için prospektif çalışmalara ihtiyaç vardır.
Bulgular:
Gruplar arasında istatiksel olarak anlamlı fark tespit edilmiştir (p=0,0001). Her üç grup arasında da anlamlı fark olduğu görüldü. Buna göre grup 1 ile grup 2 karşılaştırıldığında p=0,043 olarak, grup 1 ile grup 3 karşılaştırıldığında p=0,001 olarak ve grup 2 ile grup 3 karşılaştırıldığında p=0,0001 olarak tespit edildi.
Gereç ve Yöntemler:
Bu prospektif çalışmaya üst gastrointestinal sistem şikayetleri bulunan 60 hasta dahil edildi. Gastroskopi işlemi esnasında ERCP kanülü ile alınan gastrik sıvı örnekleri -20 derecede 6 ay saklanarak kalprotektin değerleri ölçüldü. Çalışmaya dahil edilen hastalardan doku tanısı amacıyla standart endoskopik biyopsiler alındı.
Amaç:
Kalprotektinin gastrik sıvıda varlığını ispatlayarak, gastrik kanser tanısında gastrik sıvı kalprotektininin kullanılabilirliğini değerlendirmektir.
Anahtar Kelimeler:
Kalprotektin, gastrik sıvı, tanı
Kaynaklar
1
Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of highly immunogenetic human leukocyte protein, the L1 antigen. Eur J Biochem 1983;134:1-6.
2
Stockley RA, Dale I, Hill SI, Fagerhol MK. Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease. Scand J Clin Lab Invest 1984;44:629-39.
3
Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calciumbinding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leuk Biol 1995;58:650-8.
4
Stritz I, Trebichavsky I. Calprotectin-a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53:245-53.
5
Zhao L, Wang H, Sun X, Ding Y. Comparative proteomic analysis progression of colorectal carcinoma. FEBS J 2010;277:4195-204.
6
Tøn H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjønsby H, Johne B. Improved assay for fecal cal. Clin Chim Acta 2000;292:41-54.
7
Konikoff MR, Denson LA. Role of fecal cal as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34.
8
Roseth AG, Aadland E, Jhansen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal Cal, a novel granulocyte marker protein. Digestion 1997;58:176-80.
9
Husebye E, Ton H, Johne B. Biological variability of fecal Cal in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7.
10
Kristinsson J, Armbruster CH, Ugstad M, Kriwanek S, Nygaard K, Tøn H, et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 2001;36:202-7.
11
Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjønsby H, Bormer OP, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
12
Burri E, Beglinger C. Faecal calprotectin-a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012;142:w13557.
13
Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011;56:2372-7.
14
Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-8.
15
Deshpande AR, Strobel S. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011;34:586.
16
Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol 2011;46:694-700.
17
Thuijls G, Derikx JP, Prakken FJ, Huisman B, van Bijnen Ing AA, van Heurn EL, et al. A pilot study on potential new plasma markers for diagnosis of acute appendicitis. Am J Emerg Med 2011;29:256-60.
18
Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein cal. Mol Pathol 1997;50:113-23.
19
Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18:1338-9.
20
Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Huges GRV. Cal in patients with systemic lupus erythematosous: relation to clinical and laboratory parameters of disease activity. Lupus 1993;2:47-50.
21
Golden BE, Clohessy PA, Russell G, Fagerhol MK. Cal as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996;74:136-9.
22
Stockley RA, Dale I, Hill SL, Fagerhol MK. Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease. Scand J Clin Lab Invest 1984;44:629-34.
23
Golden BE, Clohessy PA, Russell G, Fagerhol MK. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996;74:136-9.
24
Bealer JF, Colgin M. A potential new diagnostic aid for acute appendicitis. Acad Emerg Med 2010;17:333-6.
25
Carroccio A, Rocco P, Rabitti PG, Di Prima L, Forte GB, Cefalù AB, et al. Plasma calprotectin levels in patients suffering from acute pancreatitis. Dig Dis Sci 2006;51:1749-53.
